AstraZeneca's first-in-class severe asthma therapy Tezspire has been approved in the EU in a new pen injector formulation suitable for administration by patients themselves.
During The Economist’s 8th Annual World Cancer Series congress in Brussels November last year, web editor Nicole Raleigh sat down to discuss the event and its themes with
The clock has started ticking on the FDA's review of Sanofi and AstraZeneca's one-shot antibody to protect newborns and infants from respiratory syncytial virus (RSV), with a decision due i